Cancer News and Research

Latest Cancer News and Research

LJI researcher awarded $1.6 million grant to study factors that trigger onset of type 1 diabetes

The American Diabetes Association has awarded La Jolla Institute researcher Stephanie Stanford, Ph.D., a $1.6 million grant to investigate the genetic and environmental factors that trigger the onset of type 1 diabetes.

11 Jan 2015

Mayo Clinic study dispels myth that cancer biopsies cause cancer to spread

A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy.

11 Jan 2015

NCCN collaborates with Flatiron Health to create oncology outcomes database

The National Comprehensive Cancer Network is collaborating with Flatiron Health to create a cloud-based data repository of NCCN Member Institution data - the NCCN Outcomes Database.

9 Jan 2015

Orlando Regional Medical Center opens new patient tower

As the new year begins, Orlando Health turns the page to a new chapter in patient, guest and team member experience, when Orlando Regional Medical Center opens its new patient tower.

9 Jan 2015

DiaCarta raises $8 million in Series A financing from BVCF

DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.

9 Jan 2015

Crown Bioscience to double capacity of PRECOS facility, rename UK site

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced that it will double the capacity of the recently acquired PRECOS (Preclinical Oncology Services Limited) facility and will rename the site Crown Bioscience UK Ltd.

9 Jan 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that it has completed a blinded clinical study demonstrating that its NuQ® blood-based diagnostic platform is able to accurately detect 84% of early, surgically-treatable pancreatic cancers at high 92% specificity.

8 Jan 2015

New opportunity for developing simple test to measure E2F4 activity in ER+ breast cancer patients

By looking at the expression levels of downstream genes of the regulators in breast cancer, investigators at Dartmouth Hitchcock's Norris Cotton Cancer Center, led by Chao Cheng, PhD, have identified a gene signature in E2F4 that is predictive of estrogen receptor positive (ER+) breast cancer.

8 Jan 2015

Survey shows radiation oncologists desire for more formal guidance to improve peer review process

Peer review is a common practice in medicine to support the complementary, multidisciplinary team approach in healthcare. A 2013 survey of radiation oncologists indicates that they would like more formal recommendations and guidance in order to improve the peer review process, according to a study published in the January-February 2015 issue of Practical Radiation Oncology, the clinical practice journal of the American Society for Radiation Oncology.

8 Jan 2015

Improving headache treatment could reduce health care spending, new study suggests

Each year more than 12 million Americans visit their doctors complaining of headaches, which result in lost productivity and costs of upward of $31 billion annually. A new study by researchers from Beth Israel Deaconess Medical Center suggests some of that cost could be offset by physicians ordering fewer tests and an increased focus on counseling about lifestyle changes.

8 Jan 2015

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

$ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL$

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.

8 Jan 2015

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn Group and Pharmacosmos A/S today jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia.

8 Jan 2015

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

8 Jan 2015

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer.

8 Jan 2015

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax Pharmaceuticals, Inc., (Waltham, Mass.; president and CEO: Arlene M. Morris, "Syndax") today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.

7 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

Cancer News and Research

Latest Cancer News and Research

LJI researcher awarded $1.6 million grant to study factors that trigger onset of type 1 diabetes

Mayo Clinic study dispels myth that cancer biopsies cause cancer to spread

NCCN collaborates with Flatiron Health to create oncology outcomes database

Orlando Regional Medical Center opens new patient tower

DiaCarta raises $8 million in Series A financing from BVCF

Crown Bioscience to double capacity of PRECOS facility, rename UK site

Two new ODYSSEY trials meet primary efficacy endpoints

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

New opportunity for developing simple test to measure E2F4 activity in ER+ breast cancer patients

Survey shows radiation oncologists desire for more formal guidance to improve peer review process

Improving headache treatment could reduce health care spending, new study suggests

New guidance recommends use of primary HPV test for cervical cancer screening

ProNAi enrolls first patient in PNT2258 Phase II study for treatment of refractory or relapsed DLBCL

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

Kyowa Hakko Kirin and Syndax sign agreement to develop entinostat in Japan and Korea

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Understanding the DNA Damage Response in Innate Immunity eBook

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Newsletters you may be interested in